• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]

Bevacizumab for the second line treatment of HER2 negative metastatic breast cancer

Status:	Suspended
Expected date of issue:	TBC
Referral date:	November 2011
Wave:	27
Process:	STA
Notes: Scoped within Batch 19
Topic area: Cancer

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	TBC
Technical Lead:	TBC
Communications manager:	TBC
Project manager:	TBC

Top

 

Provisional schedule

Closing date for invited submissions / evidence submission:	TBC
1st appraisal committee meeting:	TBC

Top

 

Consultees and commentators

To be confirmed

Top

 

Project history

Date Update 7 November 2011 As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of bevacizumab in combination with chemotherapy for the second line treatment of human epidermal growth factor 2 (HER2) negative metastatic breast cancer as part of our 27th work programme.  The Institute has now been informed by the manufacturer that it has decided not to apply for a centralised marketing authorisation for this indication. NICE has therefore decided to suspend this appraisal on its current work programme for the time being. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

Top

 

Key documents

Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line): appendix B - draft scope for consultation (pre-referral) May 2011 07 November 2011 Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line): appendix C - provisional matrix (pre-referral) May 2011 07 November 2011

This page was last updated: 28 February 2012